Abstract Book - PDF - San Antonio Breast Cancer Symposium

CTRC-AACR San Antonio Breast Cancer Symposium
P2-11-13 The Effect of Positive Axillary Lymph Nodes on Symptoms,
Physical Impairments, and Function
Kesarwala AH, Pfalzer LA, O’Meara WP, Stout NL. National Cancer
Institute, Bethesda, MD; University of Michigan - Flint, MI; Lahey
Clinic, Burlington, MA; Walter Reed National Military Medical Center,
Bethesda, MD.
P2-11-14 Symptoms, Physical Impairments, and Function in Breast
Cancer Patients with Negative Axillary Lymph Nodes
Kesarwala AH, Pfalzer LA, O’Meara WP, Stout NL. National Cancer
Institute, Bethesda, MD; University of Michigan - Flint, MI; Lahey
Clinic, Burlington, MA; Walter Reed National Military Medical Center,
Bethesda, MD.
P2-11-15 Development of a web-based survey tool to assess change
in breast cancer (BrCa) survivor knowledge after receipt of
cancer treatment summary and survivorship care plan (SCP)
Custer JL, Rocque GB, Wisinski KB, Jones NR, Donohue S, Koehn TM,
Champeny TL, Terhaar AR, Chen KB, Peck KA, Tun MT, Wiegmann
DA, Sesto ME, Tevaarwerk AJ. University of Wisconsin, Madison, WI.
P2-11-16 Cardiac Morbidity After Adjuvant Chemotherapy (CT) for Early
Breast Cancer in the Community Setting
Patt D, Espirito J, Turnwald B, Denduluri N, Wang Y, Lina A,
Hoverman R, Neubauer M, Bosserman L, Busby L, Brooks B,
Cartwright T, Sitarik M, Schnadig I, Winter W, Garey J, Ginsburg-
Arlen A, Bergstrom K, Beveridge R. Pathways Task Force, US
Oncology Network, McKesson Specialty Health, Austin, TX;
Pathways Task Force, US Oncology Network, McKesson Specialty
Health, The Woodlands, TX; Pathways Task Force, US Oncology
Network, McKesson Specialty Health, Arlington, VA; US Oncology
Network, McKesson Specialty Health, The Woodlands, TX; Kansas
City Cancer Center, Pathways Task Force, US Oncology Network,
McKesson Specialty Health, Overland Park, KS; Pathways Task
Force, US Oncology Network, McKesson Specialty Health, Rancho
Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task
Force, US Oncology Network, McKesson Specialty Health, Boulder,
CO; Pathways Task Force, US Oncology Network, McKesson Specialty
Health, Dallas, TX; Pathways Task Force, US Oncology Network,
McKesson Specialty Health, Ocala, FL; Pathways Task Force, US
Oncology Network, McKesson Specialty Health, Tualatin, OR;
Pathways Task Force, US Oncology Network, McKesson Specialty
Health, Portland, OR.
P2-11-17 Pilot Study to Evaluate a Home-based Exercise and Weight
Loss Intervention on Cardiopulmonary Fitness and Markers of
Breast Cancer Risk in Postmenopausal Breast Cancer Survivors
Burnett D, Klemp JR, Porter C, Schmitz KJ, Fabian CJ, Kluding P.
University of Kansas Medical Center, Kansas City, KS; University
of Kansas Hospital, Kansas City, KS; University of Pennsylvania,
Philadelphia, PA.
Psychosocial, Quality of Life, and Educational Aspects: Quality of Life -
Supportive Care
P2-12-01 Prospective Evaluation of Joint Symptoms in Postmenopausal
Women Initiating Aromatase Inhibitors for Early Stage
Breast Cancer
Crew KD, Chehayeb Makarem D, Awad D, Kalinsky K, Maurer M,
Kranwinkel G, Brafman L, Fuentes D, Hershman DL. Columbia
University Medical Center, New York, NY.
P2-12-02 Withdrawn
P2-12-03 A pilot study evaluating the benefits and feasibility of an
exercise program for breast cancer patients receiving adjuvant
chemotherapy
Petrella TM, Laredo S, Oh P, Marzolini S, Warner E, Dent R, Verma S,
Eisen A, Pritchard K, Trudeau M, Zhang L, Bjarnason G. Odette Cancer
Centre, Toronto, ON, Canada; Women’s College Hospital, Toronto,
ON, Canada; Toronto Rehabilitation Institute, Toronto, ON, Canada;
Macrostat Inc, Toronto, ON, Canada.
P2-12-04 Music Therapy Reduces Radiotherapy-Induced
Fatigue in Patients with Breast or Gynecological Cancer:
A Randomized Trial
Freitas NMA, Silva TRMA, Freitas-Junior R, Paula Junior W, Silva DJ,
Machado GDP, Ribeiro MKA, Carneiro JP. Araujo Jorge Hospital/
ACCG, Goiania, Goias, Brazil; Federal University of Goias, Goiania,
Goias, Brazil; Instituto Integrado de Neurociencias/IINEURO, Goiania,
Goias, Brazil.
P2-12-05 Limited Absorption of Low Dose 10 µg Intravaginal 17-β
Estradiol (Vagifem®) in Postmenopausal Women with Breast
Cancer on Aromatase Inhibitors
Goldfarb SB, Dickler M, Dnistrian A, Patil S, Dunn L, Chang K,
Berkowitz A, Tucker N, Carter J, Barakat R, Hudis C, Castiel M.
Memorial Sloan-Kettering Cancer Center, New York, NY.
P2-12-06 Ultra-low dose vaginal estriol and Lactobacillus acidophilus
(Gynoflor®) in early breast cancer survivors on aromatase
inhibitors: Pharmacokinetic, efficacy and safety results from
a phase I study
Neven P, Donders G, Mögele M, Lintermans A, Bellen G, Ortmann
O, Buchholz S. University Hospital Gasthuisberg Leuven, Belgium;
Femicare vzw, Clinical Research for Women, Tienen, Belgium;
Universitätsklinikum Regensburg, Germany.
P2-12-07 A review of clinical endpoints and use of quality-of-life
outcomes in phase III metastatic breast cancer clinical trials
Tatla R, Landaverde D, Victor C, Miles D, Verma S. University of
Toronto, ON, Canada; Sunnybrook Odette Cancer Center, Toronto,
ON, Canada; Dalla Lana School of Public Health, University of
Toronto, ON, Canada; Mount Vernon Cancer Centre, United
Kingdom.
P2-12-08 Sorafenib for treatment of breast-cancer related lymphedema
Zambetti M, Guidetti A, Carlo-Stella C, De Benedictis E, Tessari A,
Balzarini A, Caraceni A, Gianni L, Gianni AM. IRCCS Ospedale San
Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori,
Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico
Humanitas, Rozzano, Italy.
P2-12-09 A randomized controlled trial of support group intervention
after breast cancer treatment: Results on sick leave, health
care utilization and health economy
Granstam Björneklett H, Rosenblad A, Lindemalm C, Ojutkangas
M-L, Letocha H, Strang P, Bergkvist L. Centre for Clinical Research,
Västerås, Västmanland, Sweden; Cancer Center Karolinska, Karolinska,
Stockhoöm, Sweden; Karolinska Institutet, Stockholm, Sweden.
P2-12-10 Psycho-spiritual therapy for improving the quality of life and
spiritual well-being of women with breast cancer
Loghmani A, Jafari N, Zamani A, Farajzadegan Z, Bahrami F, Emami
H. Isfahan University of Medical Sciences, Isfahan, Islamic Republic of
Iran; University of Isfahan, Islamic Republic of Iran.
P2-12-11 Use of the DigniCap System To Prevent Hair Loss in Women
Receiving Chemotherapy (CTX) for Stage I Breast Cancer (BC)
Rugo HS, Serrurier KM, Melisko M, Glencer A, Hwang J, D’Agostino,
Jr. R, Hutchens S, Esserman LJ, Melin S. University of California San
Francisco Helen Diller Comprehensive Cancer Center, San Francisco,
CA; Wake Forest Baptist Health Medical Center, Winston-Salem, NC.
P2-12-12 Efficacy and safety of scalp cooling (SC) treatment for alopecia
prevention in women receiving chemotherapy (CTX) for breast
cancer (BC)
Serrurier KM, Melisko ME, Glencer A, Esserman LJ, Rugo HS. UCSF
Helen Diller Comprehensive Cancer Center.
P2-12-13 Results of randomised controlled phase II study (KBCSG02
trial) of the efficiency of palonosetron, aprepitant, and
dexamethasone for day 1 with or without dexamethasone on
days 2 and 3
Kosaka Y, Sengoku N, Kikuchi M, Nishimiya H, Enomoto T, Kuranami
M, Watanabe M. Kitasato University School of Medicine, Sagamihara,
Japan.
Cancer Res; 72(24 Suppl.) December 15, 2012 28s Cancer Research